NCT03620643 - Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions

Lobular Breast CarcinomaGastric CancerTriple Negative Breast CancerCDH1 Gene Mutation

Interventions

DRUG

Crizotinib Oral Capsule [Xalkori]

Crizotinib 250 mg Crizotinib 200mg

DRUG

Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]

Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.

Trial Locations (5)

Unknown

Beatson West of Scotland Cancer Centre, Glasgow

Guys and St Thomas NHS Foundation Trust, London

University College London Hospital, London

The Christie NHS Foundation Trust, Manchester

SW3 6JJ

Royal Marsden NHS Foundation Trust, London